bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

1

Modeling the frequency and number of persons to test to detect and control COVID-19 outbreaks in

2

congregate settings

3

Prabasaj Paul1*, Emily Mosites1, Rebecca L. Laws1, Heather Scobie1, Rachel B. Slayton1**, Kristie E. N.

4

Clarke1**

5

Affiliation (all authors):

6

1COVID-19

Response, Centers for Disease Control and Prevention, Atlanta GA

7
8

*Corresponding

author

9

1600 Clifton Rd NE

10

MS H16-2

11

Centers for Disease Control and Prevention

12

Atlanta GA 30329

13

404-718-5287

14

VIG5@cdc.gov

15

**

These senior authors contributed equally to this article.

16
17

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily

18

represent the official position of the Centers for Disease Control and Prevention.

19

1

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

20

Modeling the frequency and number of persons to test to detect and control COVID-19 outbreaks in

21

congregate settings

22

Abstract (238 words)

23

Background: Congregate settings are at risk for coronavirus disease 2019 (COVID-19) outbreaks.

24

Diagnostic testing can be used as a tool in these settings to identify outbreaks and to control

25

transmission.

26

Methods: We used transmission modeling to estimate the minimum number of persons to test and the

27

optimal frequency to detect small outbreaks of COVID-19 in a congregate facility. We also estimated the

28

frequency of testing needed to interrupt transmission within a facility.

29

Results: The number of people to test and frequency of testing needed depended on turnaround time,

30

facility size, and test characteristics. Parameters are calculated for a variety of scenarios. In a facility of

31

100 people, 26 randomly selected individuals would need to be tested at least every 6 days to identify a

32

true underlying prevalence of at least 5%, with test sensitivity of 85%, and greater than 95% outbreak

33

detection sensitivity. Disease transmission could be interrupted with universal, facility-wide testing with

34

rapid turnaround every three days.

35

Conclusions: Testing a subset of individuals in congregate settings can improve early detection of small

36

outbreaks of COVID-19. Frequent universal diagnostic testing can be used to interrupt transmission

37

within a facility, but its efficacy is reliant on rapid turnaround of results for isolation of infected

38

individuals.

39

2

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

40
41

Background
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is a highly transmissible

42

pathogen that spreads easily in shared environments (1). Thus, congregate settings, such as long-term

43

care facilities, correctional facilities, homeless shelters, and high-density workplaces, are at increased

44

risk for outbreaks of COVID-19 (2-9). Diagnostic testing to detect SARS-CoV-2 infection in congregate

45

settings may achieve at least two key public health objectives: 1) testing can identify outbreaks,

46

triggering the application of intervention measures and further testing, and 2) testing can identify

47

infectious individuals who need to isolate to prevent further transmission.

48

We developed and applied models related to SARS-CoV-2 infectiousness, test sensitivity and

49

specificity, and time to test results to estimate both the number of people and frequency of testing

50

needed in congregate settings to achieve: 1) early detection of outbreaks and 2) transmission

51

interruption. These estimates can inform testing strategies designed to protect people living or working

52

in congregate settings and the communities in which they reside.

53
54

Materials and Methods

55

Testing for early detection of outbreaks

56

Outbreak detection was defined as identifying at least one positive test, regardless of true

57

underlying prevalence. We defined â€œearlyâ€ detection to mean identifying at least one positive result

58

before case counts surpass a set number; here we chose 2, 5, and 10 true cases. For this purpose, the

59

number of people that need to be tested in a congregate setting is dependent on the true underlying

60

prevalence of infection, and the sensitivity and the specificity of the test. We estimated the number of

61

randomly-selected individuals (n) needed to test for detection of an outbreak based on an expected

62

number of infections (ğ‘›0, commensurate with prevalence ğ‘), a minimum detection sensitivity ğ‘†, and a

3

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

63

minimum positive predictive value. When the ğ‘› required exceeded the facility size ğ‘, then the outbreak

64

was considered too small to be detected.

65

If ğ‘› individuals are randomly selected for testing (test sensitivity ğœ–, specificity ğœ‹) from a facility of

66

size ğ‘ where the prevalence of infections is ğ‘, and presence of an outbreak is indicated by at least one

67

positive test result, the probabilities of four possible outcomes are:

68

â€¢

Detection of outbreak and an outbreak exists (true positive): ğ‘‡ğ‘ƒ = 1 â€• (ğ¹ğ‘ƒ + ğ¹ğ‘ + ğ‘‡ğ‘)

69

â€¢

Detection of an outbreak but no outbreak exists (false positive): ğ¹ğ‘ƒ = (1 â€• ğ‘)ğ‘(1 â€• ğœ‹ğ‘›)

70

â€¢

No detection of an outbreak but outbreak exists (false negative): ğ¹ğ‘ = [ğ‘(1 â€• ğœ–) + (1 â€• ğ‘)ğœ‹]ğ‘›

71

â€•ğ‘‡ğ‘

72

â€¢

73

For the facility level, outbreak detection sensitivity is ğ‘† = ğ‘‡ğ‘ƒ/(ğ‘‡ğ‘ƒ + ğ¹ğ‘) and positive predictive value is

74

ğ‘ƒğ‘ƒğ‘‰ = ğ‘‡ğ‘ƒ/(ğ‘‡ğ‘ƒ + ğ¹ğ‘ƒ).

75

The true underlying prevalence of infection, ğ‘›, was determined by the rate of introduction, (ğœ‚ =

76

community incidence Ã— facility size) and the doubling time (ğœ) within the facility as:

No detection of an outbreak and no outbreak exists (true negative): ğ‘‡ğ‘ = (1 â€• ğ‘)ğ‘ğœ‹ğ‘›

ğ‘‘ğ‘›

77
78

ğ‘‘ğ‘¡

= (ln2)ğ‘›/ğœ + ğœ‚

Solving for the expected number of infections at time ğ‘¡ after first introduction (i.e., with n(0)=1) gives:
ğ‘’ğ‘¡ ln2/ğœ + (ğœ‚ğœ/ln2) (ğ‘’ğ‘¡ ln2/ğœ â€• 1).

79
80

At a facility where the rate of introduction is ğœ‚ and the doubling time is ğœ, the expected number of

81

infections at time ğ‘¡ after first introduction is:

82

ğ‘’ğ‘¡ ln2/ğœ + (ğœ‚ğœ/ln2) (ğ‘’ğ‘¡ ln2/ğœ â€• 1).

83

We assumed a community incidence of 100 cases per 100,000 people and doubling time for congregate

84

settings of 3.4 days (4). Expressions were calculated using R software v3.6.2.

85

Testing to interrupt transmission

4

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

86

To interrupt transmission (i.e., achieve a basic reproduction number below one), a successful

87

testing strategy may need to achieve at least 60% reduction in transmission (10). We estimated the

88

percent reduction in transmission for two scenarios of facility-wide testing: 1) both test-positive and

89

symptomatic individuals are isolated, and 2) only test-positive individuals are isolated (appropriate in

90

settings where symptom ascertainment is difficult). Expressions were also calculated using R 3.6.2.

91

We used the infectivity profile of COVID-19 estimated by He et al. (11). We also used an

92

assumption that presymptomatic infections account for 50% of transmission and 40% of infections are

93

asymptomatic (12). In our model, test sensitivity ranged 85%â€“95%, depending on both the test type and

94

time since exposure (i.e., more sensitive during times of high viral load) (13).

95

If the infectiousness of an infected individual is ğ¼(ğ‘¡) (normalized to unity), where ğ‘¡ is the time

96

since exposure, and the fraction of infected individuals who have already shown symptoms at ğ‘¡ is ğœ(ğ‘¡),

97

then the proportion of transmissions eliminated on isolation of symptomatic individuals, ğ‘ƒğ‘ , is:
âˆ

98

ğ‘ƒğ‘  =

ğœ (ğ‘¡)ğ¼(ğ‘¡) ğ‘‘ğ‘¡.
0

99
100

101

If testing is repeated on the same individual at regular intervals ğ‘‡, then the mean proportion of
asymptomatic transmissions eliminated is:

1
ğ‘ƒğ‘(ğ‘‡,ğ‘¡ğ‘™) =
ğ‘‡

ğ‘‡

âˆ

ğ‘›

ğœŒğ‘ (ğ‘¡ + ğ‘›ğ‘‡,ğ‘¡ğ‘™)
0 ğ‘›=0

[ 1 â€• ğ‘ (ğ‘¡ + ğ‘˜ğ‘‡ â€• ğ‘‡)] ğ‘‘ğ‘¡.
ğ‘˜=0

102

If an asymptomatic infected individual is tested at time ğ‘¡0 after infection, with test sensitivity ğ‘ (ğ‘¡0), and

103

the test result is available after a reporting lag ğ‘¡ğ‘™ at ğ‘¡1 = ğ‘¡0 + ğ‘¡ğ‘™, the additional proportion of

104

transmissions eliminated, ğœŒğ‘, is:
âˆ

105

ğœŒğ‘(ğ‘¡0,ğ‘¡ğ‘™) = ğ‘ (ğ‘¡0)

[ 1 â€• ğœ(ğ‘¡)]ğ¼(ğ‘¡) ğ‘‘ğ‘¡.
ğ‘¡1

106

If testing is repeated on the same individual at regular intervals ğ‘‡, then the mean proportion of

107

asymptomatic transmissions eliminated is:
5

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

1
ğ‘ƒğ‘(ğ‘‡,ğ‘¡ğ‘™) =
ğ‘‡

108

ğ‘‡

âˆ

ğ‘›

ğœŒğ‘ (ğ‘¡ + ğ‘›ğ‘‡,ğ‘¡ğ‘™)
0 ğ‘›=0

[ 1 â€• ğ‘ (ğ‘¡ + ğ‘˜ğ‘‡ â€• ğ‘‡)] ğ‘‘ğ‘¡.
ğ‘˜=0

109

The sum accounts for those who tested true positive when first tested, as well as those who tested false

110

negative once, twice, etc. followed by a true positive.

111
112

Results

113

Testing for early detection of outbreaks

114

We estimated the number of individuals needed to test for early outbreak identification for 18

115

scenarios (Table 1), which required testing between 16% and 90% of individuals, depending on facility

116

size and true cluster size. For a facility of 100 people, 47 individuals would need to be tested to identify

117

at least one positive result if there were truly 5 cases (5% prevalence) with test sensitivity of 85%, and

118

greater than 95% outbreak detection sensitivity.

119

Table 1: Number of individuals needed to test to detect at least one positive result at facilities of

120

varying sizes given different numbers of cases present (test sensitivity 85%, detection sensitivity â‰¥

121

95%)

Facility Size

30
50
100
150
300
500
122

*Positive

Number of cases at facility
2 cases 5 cases 10 cases
Number of individuals needed
to test
27
17
9
42
27
15
69*
47
28
86*
61
38
110*
87
61
123*
104
80

predictive value < 90%

123

The frequency of testing for detection at a facility should not exceed the time from first

124

introduction of an infected person from the community to the maximum threshold of allowable

125

infections, ğ‘›0. At a 100-person facility located in a community with an incidence of 100 infections per
6

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

126

100,000 daily, an introduction from the community can be expected to occur on average every 10 days,

127

and a 5% prevalence would be attained 6 days after introduction (Table 2). Therefore, the interval

128

between tests should not exceed 6 days to detect an outbreak at 5% prevalence or lower.

129

Table 2: Average number of daysâ€”from first introduction of an infected individual from the

130

communityâ€”to reach a given number of infections at facilities of varying sizes

131
132
133
134
135

Days until x number of cases reached
Average number of
Facility Size*
days between
2 cases
5 cases
10 cases
introductions**
30
33 days
3 days
7 days
11 days
50
20 days
3 days
7 days
10 days
100
10 days
3 days
6 days
10 days
150
7 days
2 days
6 days
9 days
300
3 days
2 days
5 days
8 days
500
2 days
1 day
4 days
6 days
*Doubling time is 3.4 days within the facility regardless of size.
**If true community incidence is 100 infections daily per 100,000, this is the average number of days in
between introduction of infected individuals to the facility, given the facility size.
Testing to interrupt transmission

136

With no testing, isolation of symptomatic individuals at symptom onset alone would achieve a

137

33% reduction in transmission (Figure 1A). When symptom-based isolation and testing with immediate

138

results (within 15 minutes) were combined, a 60% reduction in transmission (i.e., R0 <1) (1) would be

139

achieved if tests were administered at least every 3 days. A 60% reduction in transmission would also be

140

achieved by administering tests every 2 days if there was a 24-hour delay in results reporting, and by

141

administering tests daily with a 36-hour delay in results.

142

Using testing alone without additional isolation of symptomatic individuals (Figure 1B) would

143

require more frequent testing to achieve a 60% reduction in transmission. Daily testing would be

144

required if results were available in 24 hours and testing every 2 days required if there was a 12-hour

145

delay in test results.

7

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

146

Figure 1. (A) Scenario 1, Reduction in transmission (%) through isolation of test-positive and

147

symptomatic individuals. (B) Scenario 2, Reduction in transmission (%) through isolation of test-

148

positive individuals only.

149
150
151

Discussion
Numerous COVID-19 outbreaks have occurred in congregate settings, sometimes with high

152

morbidity and mortality (2-9). In this modeling study, we found that early identification of an outbreak

153

of 5 cases in a facility could be achieved by testing from 21% to 57% of individuals, depending on facility

154

size. Minimal testing intervals were estimated (e.g., every 6 days for a 100 person facility), but more

155

frequent testing would increase the likelihood of early detection. Testing frequency should take into

156

account facility size. Detection of cases among a sample of the facility population would indicate a need

157

for facility-wide testing and other intervention measures to interrupt transmission.

158

Using testing as a tool to interrupt transmission required a much higher frequency of testing,

159

generally every 3 days or fewer, particularly if there are reporting lags in receiving test results (i.e., 1â€“3

160

days vs. 15 minutes). Findings regarding testing frequency align with another recent modeling study

161

focused on institutes of higher education (14). Ultimately, the frequency of testing at a facility will

162

depend on the balance between risk tolerance, frequency of introducing infections, and resource

163

availability.

164

One limitation of this analysis is that we applied general formulas that did not account for

165

specific characteristics of individuals residing in and working in these congregate settings. Furthermore,

166

uncertainties in the modeling parameters introduce imprecision in derived estimates. These values can

167

provide starting points for consideration for testing strategies but should not be considered definitive.

168

As additional data become available, parameter estimates can be refined and models can be fitted to

169

the best available data.
8

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

170

To reduce transmission, testing should always be used in combination with other prevention

171

measures including social distancing, wearing masks and cloth face coverings, hand hygiene, cleaning

172

and disinfection, screening, and isolation of individuals that are symptomatic or test positive, and

173

quarantine of their close contacts. In coordination with these measures, testing strategies may reduce

174

morbidity and mortality among individuals in congregate settings, prevent further spread into the

175

community, and decrease strain on healthcare systems.

176
177

Acknowledgments

178

The authors would like to thank Dr. Eric Mooring for his thoughtful review of the manuscript.

179
180

References

181

1. Sanche S, Lin Y, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid

182

Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020;26(7):1470-

183

1477.

184

2. McMichael TM, Clark S, Pogosjans S, Kay M, Lewis J, Baer A. COVID-19 in a Long-Term Care Facility

185

â€” King County, Washington, February 27â€’March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar

186

27;69(12):339â€’342.

187

3. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and

188

Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility â€”

189

King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):377â€’381.

190

4. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2

191

Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020 May 28;

192

382(22):2081â€’2090.

9

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

193

5. Mosites E, Parker EM, Clarke KEN, Gaeta JM, Baggett TP, Imbert E, et al. Assessment of SARS-CoV-2

194

Infection Prevalence in Homeless Shelters â€” Four U.S. Cities, March 27â€’April 15, 2020. MMWR

195

Morb Mortal Wkly Rep. 2020 May 1;69(17):521â€’522.

196
197
198

6. Baggett TP, Keyes H, Sporn N, Gaeta JM. Prevalence of SARS-CoV-2 Infection in Residents of a Large
Homeless Shelter in Boston. JAMA. 2020 Apr 27;323(21):2191â€’2192.
7. Wallace M, Hagan L, Curran KG, Williams SP, Handanagic S, Bjork A, et al. COVID-19 in Correctional

199

and Detention Facilities â€” United States, Februaryâ€’April 2020; MMWR Morb Mortal Wkly Rep. 2020

200

May 15;69(19):587â€’590.

201

8. Njuguna H, Wallace M, Simonson S, Tobolowsky FA, James AE, Bordelon K. Serial Laboratory Testing

202

for SARS-CoV-2 Infection Among Incarcerated and Detained Persons in a Correctional and Detention

203

Facility â€” Louisiana, Aprilâ€’May 2020. MMWR Morb Mortal Wkly Rep. 2020 July 3;69(26):836â€’840.

204

9. Dyal JW, Grant MP, Broadwater K, Bjork A, Waltenburg MA, Gibbins JD, et al. COVID-19 Among

205

Workers in Meat and Poultry Processing Facilities â€” 19 States, April 2020. MMWR Morb Mortal

206

Wkly Rep. 2020 May 8;69(18):557â€’561.

207

10. Delamater PL, Street EJ, Leslie TF, Yang Y, Jacobsen KH. Complexity of the Basic Reproduction

208

Number (R0). Emerg Infect Dis. 2019;25(1):1-4. https://dx.doi.org/10.3201/eid2501.171901

209

11. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and

210
211

transmissibility of COVID-19. Nat Med. 2020 Apr 15;26:672â€’675.
12. Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios. 2020. Accessed

212

July 13, 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-

213

scenarios.html.

214

13. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus

215

disease 2019 [published online ahead of print, 2020 Mar 28]. Clin Infect Dis. 2020;ciaa344.

216

doi:10.1093/cid/ciaa344
10

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.20.391011; this version posted November 20, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC
105 and is also made available for use under a CC0 license.

217

14. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe

218

Reopening of College Campuses in the United States. JAMA Netw Open. 2020;3(7):e2016818.

219

doi:10.1001/jamanetworkopen.2020.16818

11

